Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

NCT02058680 is registered in ClinicalTrials.gov with OncBioMune Pharmaceuticals as lead sponsor.

NCT NCT02058680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02058680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients
Lead sponsor
OncBioMune Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2012
Completion date
December 31, 2018
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer